Report cover image

Macular Degeneration Pipeline Analysis Report

Publisher Expert Market Research
Published Aug 28, 2024
Length 150 Pages
SKU # EMAR19136060

Description

Macular Degeneration Pipeline Analysis Report


Macular Degeneration Drug Pipeline Analysis 2024 The market is significantly driven by the increasing prevalence of macular degeneration, affecting nearly 20 million Americans and around 200 million people around the world. Advances in diagnostic imaging, such as OCT and AI-enhanced detection, are improving early diagnosis and monitoring. The development of gene and stem cell therapies offers promising long-term or curative treatments. Additionally, the market is witnessing increased investment in R&D and a surge in regulatory approvals for innovative drugs targeting both wet and dry AMD. These trends underscore a dynamic landscape focused on enhancing patient outcomes and reducing the disease burden. Key Takeaways • Major companies involved in the macular degeneration drug pipeline market are CHABiotech CO., Ltd., F. Hoffmann-La Roche AG, GSK Plc., Allegro Ophthalmics, LLC, Bayer AG, IVERIC bio, Inc., Allergan Inc., and others. • Current drug pipeline for macular degeneration includes OCU410, RGX-314, Izervay (avacincaptad pegol), among others. • Regulatory agencies are providing support through fast-track approvals and special designations for promising new treatments. This regulatory environment encourages the rapid development and availability of innovative therapies for patients in need. Report Coverage The pipeline analysis for macular degeneration drugs, as covered in the report, offers a comprehensive overview of the latest advancements and ongoing clinical trials in the field. The report highlights significant progress in gene therapies, which are being developed to provide long-term or potentially curative treatments for both dry and wet forms of age-related macular degeneration (AMD). Additionally, the analysis covers innovative approaches such as stem cell therapies, aimed at replacing damaged retinal cells, and novel imaging technologies that enhance early diagnosis and treatment monitoring. The competitive landscape is thoroughly examined, detailing collaborations and strategic partnerships that are accelerating research and development. The report also discuss the regulatory milestones achieved by several investigational drugs, underscoring their potential impact on future treatment paradigms. These insights reflect a dynamic and evolving pipeline that holds promise for more effective and less invasive treatment options for patients with macular degeneration. Macular Degeneration Drug Pipeline Outlook Macular Degeneration, specifically Age-related Macular Degeneration (AMD), is a medical condition affecting the macula, the central part of the retina, leading to vision loss in the centre of the visual field. It primarily affects older adults and is classified into two types: dry (atrophic) and wet (neovascular or exudative). Dry AMD is more common and progresses slowly, while wet AMD is less common but more severe, characterised by abnormal blood vessel growth under the retina. In 2023, significant advancements in the treatment of macular degeneration have been made. The FDA approved SYFOVRE (pegcetacoplan injection), the first therapy specifically targeting geographic atrophy (GA), an advanced form of dry AMD. This approval marks a milestone, offering patients a treatment to slow the progression of GA and potentially preserve vision. Additionally, the FDA approved Izervay (avacincaptad pegol intravitreal solution) for geographic atrophy secondary to age-related macular degeneration. Clinical trials demonstrated that Izervay significantly reduces the rate of GA progression, providing a new, effective option for managing this debilitating condition These approvals and ongoing developments underscore the dynamic and evolving nature of therapeutic options for macular degeneration, providing hope for improved patient outcomes. Macular Degeneration - Pipeline Drug Profiles Recent developments in the treatment of macular degeneration have introduced several promising drugs currently in clinical trials, reflecting significant advancements in the field. • OCU410 by Ocugen Inc. OCU410 is a pioneering one-time gene therapy designed for advanced dry macular degeneration (dry AMD) or geographic atrophy (GA). This therapy aims to modulate multiple pathways involved in dry AMD progression, including lipid metabolism, inflammation, oxidative stress, and complement activation. It is currently undergoing safety and efficacy trials, with the potential to halt disease progression and possibly restore some vision, marking a significant step forward in AMD treatment. • RGX-314 by Regenxbio RGX-314 is another innovative gene therapy in clinical trials for wet AMD. This therapy targets the reduction of frequent anti-VEGF injections by delivering a gene encoding a monoclonal antibody fragment that neutralizes VEGF activity. By addressing VEGF, RGX-314 aims to provide a more sustainable treatment option, reducing the burden on patients and potentially offering longer-lasting effects compared to traditional therapies. • Izervay (avacincaptad pegol) Recently approved by the FDA, Izervay targets geographic atrophy secondary to age-related macular degeneration. Clinical trials have demonstrated that Izervay significantly slows disease progression by inhibiting the complement system activity, providing new hope for patients suffering from GA. This approval underscores the drug’s efficacy in addressing one of the advanced forms of AMD, offering a much-needed therapeutic option for patients. Drug Pipeline Therapeutic Assessment This section of the report covers the analysis of Macular Degeneration Drug based on various segmentations such as: Breakup by Drug Class • Anti-VEGF Drugs These drugs inhibit vascular endothelial growth factor (VEGF), which promotes the growth of abnormal blood vessels in wet AMD. Common anti-VEGF drugs include Ranibizumab (Lucentis), Aflibercept (Eylea), and Bevacizumab (Avastin). • Photodynamic Therapy (PDT) Verteporfin (Visudyne) is used in PDT, where the drug is activated by a laser to destroy abnormal blood vessels. • Antioxidant Vitamins and Zinc The AREDS and AREDS2 formulas, which include vitamins C and E, zinc, copper, lutein, and zeaxanthin, are recommended for dry AMD to slow progression. Breakup by Phase • According to EMR analysis, Phase II clinical trials dominate the macular degeneration drug pipeline, accounting for a significant portion of ongoing research. With over 550 drugs currently in Phase II, this stage covers the majority share of the total clinical trials conducted, underscoring the robust development efforts in this critical phase. • Preclinical Phase: Laboratory and animal studies to assess safety and efficacy. • Phase I: Small-scale human trials focusing on safety and dosage. • Phase II: Larger trials to evaluate efficacy and side effects. • Phase III: Large-scale trials to confirm effectiveness, monitor side effects, and compare with standard treatments. • Phase IV: Post-marketing studies to gather more information on risks, benefits, and optimal use. Macular Degeneration Drug Clinical Trials Assessment- Competitive Dynamics Here are a few notable participants involved in macular degeneration research and development: • CHABiotech CO., Ltd CHABiotech CO., Ltd, a South Korean biotechnology company, is actively engaged in the development of advanced therapies for various medical conditions, including macular degeneration. The company specialises in regenerative medicine and cell therapy, utilising its proprietary stem cell technology to create innovative treatments. CHABiotech's involvement in macular degeneration research focuses on developing cell-based therapies to restore damaged retinal cells and improve vision. Their approach aims to leverage stem cell potential to regenerate retinal tissues, offering a promising solution for patients suffering from age-related macular degeneration (AMD). • F. Hoffmann-La Roche AG F. Hoffmann-La Roche AG, a Swiss multinational healthcare company, is a leading player in the macular degeneration drug development landscape. The company is known for its robust pipeline of innovative therapies, particularly in ophthalmology. Roche is involved in the clinical development of novel treatments for both wet and dry forms of AMD. Their research focuses on creating biologics that target key pathways involved in the progression of macular degeneration. Through strategic partnerships and cutting-edge research, Roche aims to bring breakthrough therapies to market that can significantly improve patient outcomes. • GSK Plc. GSK Plc., a British multinational pharmaceutical company, has been investing in the development of treatments for macular degeneration. While traditionally known for its vaccines and respiratory products, GSK has expanded its research into ophthalmology. The company's involvement in macular degeneration includes exploring innovative drug candidates that can slow or halt the progression of AMD. GSK's approach often involves leveraging its extensive expertise in immunology and genetic research to discover new therapeutic targets and develop effective treatments for retinal diseases. • Allegro Ophthalmics, LLC Allegro Ophthalmics, LLC, based in the United States, is focused on the development of novel therapies for vitreoretinal diseases, including macular degeneration. The company specialises in integrating small molecule therapeutics to treat eye diseases. Allegro's primary focus is on its proprietary drug candidates that target integrin pathways to reduce abnormal blood vessel growth and inflammation in the retina. These treatments aim to provide new options for patients with wet AMD, potentially offering more effective and longer-lasting results compared to existing therapies. • Bayer AG Bayer AG, a German multinational pharmaceutical and life sciences company, is heavily involved in the macular degeneration treatment landscape. Bayer has a strong portfolio in ophthalmology, with a particular focus on anti-VEGF therapies. The company collaborates with various research institutions and biotech companies to develop next-generation treatments for AMD. Bayer's commitment to innovation in eye care is reflected in its continuous efforts to enhance the efficacy and safety profiles of its therapeutic offerings, aiming to address the unmet needs of patients with macular degeneration. These advancements represent significant steps forward in macular degeneration treatment, potentially offering more effective and less burdensome options for patients. Reasons To Purchase This Report The Macular Degeneration Drug pipeline analysis report offers invaluable insights into the latest advancements and future trends in macular degeneration treatment. It provides detailed evaluations of emerging therapies, pipeline assessment, and competitive landscape analysis, enabling informed investment decisions and strategic planning. Key Questions Answered in the Macular Degeneration Drug Pipeline Analysis Report • What is the current state of the macular degeneration drug pipeline? • How many companies are currently involved in macular degeneration drug development? • What is the number of drugs in Phase III and Phase IV trials for macular degeneration? • Which organisations are at the forefront of macular degeneration drug research? • What are the effectiveness and safety profiles of the drugs in the macular degeneration pipeline? • What opportunities and challenges exist in the macular degeneration clinical trial landscape? • Which companies are leading the major clinical trials for macular degeneration drugs? • Which regions are involved in clinical trials for macular degeneration? • What are the recent clinical trial results for macular degeneration drugs? • What are the emerging trends in macular degeneration clinical trials?

Table of Contents

150 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Macular Degeneration
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Macular Degeneration
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Macular Degeneration: Epidemiology Snapshot
5.1 Macular Degeneration Incidence by Key Markets
5.2 Macular Degeneration– Patients Seeking Treatment in Key Markets
6 Macular Degeneration: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Macular Degeneration: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Macular Degeneration, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Macular Degeneration Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Macular Degeneration Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Anecortave Acetate
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Ranibizumab
10.2.3 Aflibercept
10.2.4 Other Drug
11 Macular Degeneration Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 MA09-hRPE
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Anecortave Acetate
11.2.3 Avacincaptad Pegol
11.2.4 Other Drugs
12 Macular Degeneration Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 ALG 1001
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 AdGVPEDF.11D
12.2.3 BI 754132
12.2.4 Other Drugs
13 Macular Degeneration Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 HG202
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 BD311
13.2.3 MB-102
13.2.4 Other Drugs
14 Macular Degeneration, Key Drug Pipeline Companies
14.1 CHABiotech CO., Ltd
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 F. Hoffmann-La Roche AG
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 GSK Plc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Allegro Ophthalmics, LLC
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Bayer AG
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 IVERIC bio, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Allergan Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us